Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000756

Drug Information
NameTetrabenazine    
Synonyms9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11-beta-hexahydro-2H-benzoquinolizine; Nitoman; 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-Benzo[a]quinolizin-2-one; Tetrabenazine [INN:BAN]; HMS1540E17; SMR000718664; Nitoman, Xenazine, Tetrabenazine; 2H-Benzo[a]quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-; MLS001249426; Tetrabenazinum; Tetrabenazinum [INN-Latin]; NSC172187; 2H-Benzo[a]quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11.beta.-hexahydro-2H-benzoquinolizine; 5-21-13-00178 (Beilstein Handbook Reference); Tetrabenazina; WLN: T B666 DV GNTT&J E1Y1&1 LO1 MO1; NCGC00160421-02; Xenazine (TN); STK678061; Tetrabenzaine; CHEMBL117785; UNII-Z9O08YRN8O; S1789_Selleck; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo(a)quinolizin-2-one; TL8005032; BRD-A47564106-001-01-8; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one; MLS001249497; CHEBI:293281; C11168; 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-; AI3-52046; AC1L1LMF; Tetrabenzine; BRN 0040090; NSC169886; NSC 169886; tetra Benazin; D08575; ST028814; TETRABENAZINE; CID6018; 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; EINECS 200-383-6; Tetrabenazina [INN-Spanish]; MLS003106727; 58-46-8; LS-40294; MolPort-002-712-672; Ro 1-9569; 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)- (9CI); Oprea1_264344; Xenazine; NCGC00160421-01; DB04844; Nitoman (TN); Ro 1-9569/12; 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; TimTec1_002217; A2708/0115225; Tetrabenazine (INN); Rubigen; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; AKOS001681311    
Trade NameNitoman; Xenazine    
IndicationHyperkinetic movement disorderApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassNephropathic cystinosis therapy    
CAS NumberCAS 58-46-8
FormularC19H27NO3    
PubChem Compound IDCID 6018.    
PubChem Substance IDSID 13350.    
SuperDrug ATC IDN05AK01;    
SuperDrug CAS ID000058468;    
TargetSynaptic vesicle amine transporterBlocker[2][3]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021894 To Reference
Ref 2Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8. To Reference
Ref 311C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med. 2009 Mar;50(3):382-9. Epub 2009 Feb 17. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543